Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+-K+ ATPase

Canadian Journal of Physiology and Pharmacology

Volumn 77, Issue 11, 1999, Pages 866-870

  Almotrefi, Abdulrahman A ^a,b   Basco, Chona ^b   Moorji, Azadali ^b   Dzimiri, Nduna ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Class I antiarrhythmic agents; Na+ K+ ATPase; Ouabain binding; Proarrhythmias

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIARRHYTHMIC AGENT; DIGITALIS GLYCOSIDE; DISOPYRAMIDE; ENCAINIDE; LIDOCAINE; LORCAINIDE; OUABAIN; PHENYTOIN; PROCAINAMIDE; QUINIDINE; TOCAINIDE;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GUINEA PIG; HEART MUSCLE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

EID: 0033378758     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y99-091     Document Type: Article

References (35)

1. +-ATPase -structure and kinetics. Edited by J.C. Skou and J.G. Norby. Academic Press, London, pp. 405-423.
2. +-ATPase activity. Res. Commun. Chem. Pathol. Pharmacol. 69: 253-256.
3. +-ATPase in guinea-pig isolated heart preparations. Br. J. Pharmacol. 102: 530-532.
4. +-ATPase activity. Br. J. Pharmacol. 104: 793-796.
5. Aronson, R.S., and Nordin, C. 1988. Arrhythmogenic interaction between low potassium and ouabain in isolated guinea-pig ventricular myocytes. J. Physiol. (London), 400: 113-134.
6. Bigger, J.T., and Sahar, D.I. 1987. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am. J. Cardiol. 59: 2E-9E.
7. + channels: local anesthetics, antiarrhythmics and anticonvulsants. Trends Pharmacol. Sci. 8: 57-65.
8. Charlemagne, D. 1993. Molecular and cellular level of action of digitalis. Herz, 18: 79-85.
9. Dzimiri, N. 1993. Effects of procainamide, tocainide and phenytoin on guinea pig cardiac mitochondrial ATPase activity. Res. Commun. Chem. Pathol. Pharmacol. 80: 121-124.
10. +-ATPase by two class IA antiarrhythmic drugs: quinidine and procainamide. Arch. Int. Pharmacodyn. Ther. 314: 34-43.
11. +-ATPase in guinea pig heart preparations. Gen. Pharmacol. 22: 403-406.
12. Erdmann, E., Brown, L., and Werdan, K. 1984. Two receptors for cardiac glycosides in the heart. In Cardiac glycoside receptors and positive inotropy, evidence for more than one receptor? Edited by E. Erdmann. Steinkopff Verlag, Darmstadt, pp. 21-34.
13. + channels by antiarrhythmic drugs, neurotransmitters and hormones. Trends Pharmacol. Sci. 13: 352-358.
14. Haverkamp, W.T., Witchter, T., Chen, X., Hordt, M., Willems, S., Rotmaan, B., Hindricks, G., Kottkamp, H., Borggrefe, M., and Breithardt, G. 1994. The pro-arrhythmic effects of antiarrhythmic drugs. Zeitschr. Kardiol. 83: 75-85.
15. Honerjäger, P., Loibl, E., Stedl, I., Schönsteiner, G., and Ulm, K. 1986. Negative inotropic effects of tetrotoxin and seven class I antiarrhythmic drugs in relation to sodium channel blockade. Naunyn Schmiedebergs Arch. Pharmacol. 332: 184-195.
16. Kass, R.S., Tsien, R.W., and Weingart, R. 1978. Ionic basis of transient inward current induced by strophanthidin in cardiac Purkinje fibres. J. Physiol. (London), 281: 209-226.
17. Keefe, D.L. 1984. Pharmacology of iorcainide. Am. J. Cardiol. 54: 18B-21B.
18. Kotyk, A., and Amler, E. 1995. Na,K-adenosinetriphosphatase: the paradigm of a membrane transport protein. Physiol. Res. 44: 261-274.
19. Kyte, J. 1981. Molecular considerations relevant to the mechanism of active transport. Nature (London), 292: 201-204.
20. Levine, J.H., Morganroth, J., and Kardish, A.H. 1989. Mechanism and risk factors for proarrhythmia with type Ia compared with type Ic antiarrhythmic drug therapy. Circulation, 80: 1063-1069.
21. McDonough, A.A., Wang, J., and Farley, R.A. 1995. Significance of sodium pump isoforms in digitalis therapy. J. Mol. Cell. Cardiol. 27: 1001-1009.
22. +-ATPase. Heart Dis. Stroke, 2: 250-255.
23. Milligan, G., and Bond, R.A. 1997. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18: 468-474.
24. Milligan, G., Bond, R.A., and Lee, M. 1995. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16: 10-13.
25. Morganroth, J. 1992. Early and late proarrhythmia from antiarrhythmic drug therapy. Cardiovasc. Drug Ther. 6: 11-14.
26. Nordrehaug, J.E., Johannessen, K.A., and von der Lippe, G. 1985. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation, 71: 645-649.
27. (+)-ATPase. FEBS Lett. 359: 107-109.
28. Rosen, M.R. 1995. Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. J. Cardiovasc. Electrophysiol. 6: 868-879.
29. Schlepper, M. 1989. Cardiodepressive effects of antiarrhythmic drugs. Eur. Heart J. 10(Suppl. E): 73-80.
30. + transporting ATPase from human and guinea-pig muscle through use of digitalis derivatives as analytic probes. Naunyn Schmiedebergs Arch. Pharmacol. 351: 282-292.
31. Seipel, L., and Hoffmeister, M.H. 1989. Hemodynamic effects of antiarrhythmic drugs: negative inotropy versus influence on peripheral circulation. Am. J. Cardiol. 64: 37J-40J.
32. Sheldon, R.S., Hill, R.J., and Duff, H.J. 1989. Antiarrhythmic drugs and the cardiac sodium channel. Current models. Clin. Chem. 35: 748-754.
33. Smith, T.W, Antman, E.M., Friedman, P.L., Blatt, C.M., and Marsch, J.D. 1984. Digitalis glycosides: mechanism and manifestation of toxicity. Prog. Cardiovasc. Dis. 26: 495-540.
34. Wallick, E.T., Lane, L.K., and Schwartz, A. 1979. Biochemical mechanism of the sodium pump. Annu. Rev. Physiol. 41: 397-411.
35. Wilson, R.A., Soci, L.K., Bezstarosti, K., Lamers, J.M., and Verdour, P.D. 1993. Negative inotropy of lidocaine: possible biochemical mechanism. Eur. Heart J. 14: 284-289.